Germany and France issued a joint declaration aimed at strengthening the pharmaceutical industry across Europe, announcing the agreement at the World Health Assembly (WHA) in Geneva. The German Federal Ministry of Health released the details on Tuesday.
The core objectives of the declaration are to strengthen Germany’s position and ensure long-term access to high-quality, innovative healthcare provision. To guarantee continuous bilateral exchange, a dedicated German-French ministerial working group will be established.
German Federal Minister of Health, Nina Warken, stated that the declaration deepens the bilateral ties between the two nations in a crucial sector covering both supply and economy. She emphasized that “Europe must strengthen its role as a global site for pharmaceutical research, development, and production”. She noted that Germany and France stand together to meet global challenges, aiming “to improve the framework conditions for a resilient and future-proof drug landscape”.
According to the Ministry, the declaration outlines several concrete goals. These include accelerating and harmonizing clinical studies, making the introduction of new therapies easier through mandatory European benefit evaluations, creating incentives for pharmaceutical production within the EU, securing a balanced equilibrium between environmental regulations and regional industrial interests, and strengthening intellectual property protection.
Working with France, Germany plans to support long-term structural reforms at the EU level. These reforms are aimed at restoring and maintaining the attractiveness and resilience of the entire drug supply chain.
